Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $15.2800 (36.06%) ($14.2100 - $16.5800) on Thu. May. 16, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.13% (three month average) | RSI | 73 | Latest Price | $15.2800(36.06%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA advances 8.4% a day on average for past five trading days. | Weekly Trend | IOVA advances 2.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(49%) XBI(48%) ARKG(47%) IWO(43%) ARKK(41%) | Factors Impacting IOVA price | IOVA will decline at least -3.065% in a week (0% probabilities). VXX(-16%) UUP(-9%) VIXM(-7%) IFRA(-5%) TLT(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.065% (StdDev 6.13%) | Hourly BBV | 0 () | Intraday Trend | 1.9% | | | |
|
5 Day Moving Average | $11.72(30.38%) | 10 Day Moving Average | $11.43(33.68%) | 20 Day Moving Average | $11.26(35.7%) | To recent high | 0% | To recent low | 62.9% | Market Cap | $2.238b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |